Drug Use Analysis on Over-60-year Outpatients with Lung Cancer in the West China Hospital of Sichuan University in 2011_Chinese Journal of Evidence-Based Medicine

Authors：

 WUBin ¹ ,  XUTing ¹ ,  LIYou-ping ² , LUJing ¹ , ZHANGYing ¹ , ZHANMei ¹ , YINXi ¹ , XIAOGui-rong ¹

1. Department of Pharmacy, West China Hospital, Sichuan University, Chengdu 610041, China;
2. Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu 610041, China;

Corresponding?author：

XUTing, Email: tingx2009@163.com; LIYou-ping, Email: yzmylab@hotmail.co

Keywords：

Lung cancer; Elderly; Outpatient; Drug use analysis; West China Hospital of Sichuan University

DOI：

10.7507/1672-2531.20140188

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To retrospectively investigate the medication structure and evaluate the rationality among over-60-year outpatients with lung cancer in the West China Hospital of Sichuan University in 2011. Methods The data was extracted from the hospital information system (HIS). Excel 2010 software was used for statistical analysis. Results a) The total of over-60-year outpatients with lung cancer were 17 296 person-times, of which 12 606 persons-times patients with no medication accounted for 72.88%. The monotherapy in patients with medication accounted for 75.76%. b) There were 5 types of tumour related drugs, including 56 kinds of different drugs, and the total frequency was 6 460 and the average cost was 2 219.38 yuan. The first three drugs classified by 5 types were traditional Chinese drugs (TCM, 28.50%), other therapy (24.91%), and etiological treatment (22.23%). c) For etiological treatment, tyrosine kinase inhibitors (TKI) accounted for 59.96%, and the first three drugs were gefitinib, recombinant human endostatin, and erlotinib. d) For symptomatic treatment, analgesic drugs accounted for 43.65%; and the first three drugs were tramadol hydrochloride sustained-release tablets, sodium zoledronic oxycodone, and acetaminophen. e) For ADR therapy, liver drugs accounted for 40.97%; and the first three drugs were palonosetron hydrochloride, licorice, and diammonium pantoprazole. f) Other treatment involved immunopotentiating drugs and hematopoietic growth factors, the ratios were 62.65% and 37.35%, and the first three drugs were thymalfasin, thymopentin, and recombinant interleukin-11. g) Huisheng, Banao capsule and Bailing capsule were at the first three usage in TCM, the ratios of which were 51.06%, 15.37%, and 13.91%. h) The top ten drugs were Huisheng oral liquid, gefitinib and thymus AFP, thymopentin recombinant interleukin-11, chelating compound spot capsules, recombinant human endostatin, tramadol hydrochloride extended release tablets, sodium, zole dronic, and Bailing capsule. Conclusion The antitumor therapies were mainly TKI single drug regimen for over-60-year outpatients with lung cancer in the West China hospital of Sichuan University in 2011. The most frequently used adjuvant therapies are antalgic, antitussive and skeletal related events prevention drugs. Besides, Chinese patent medicines are in common use as well.

Citation： WUBin, XUTing, LIYou-ping, LUJing, ZHANGYing, ZHANMei, YINXi, XIAOGui-rong. Drug Use Analysis on Over-60-year Outpatients with Lung Cancer in the West China Hospital of Sichuan University in 2011. Chinese Journal of Evidence-Based Medicine, 2014, 14(10): 1165-1170. doi: 10.7507/1672-2531.20140188 Copy

1.	伏紹宏, 李俊霞.四川省人口老齡化及老齡產業發展態勢及對策研究.理論與改革, 2012, 5(4):77-79.
2.	徐珽, 盧靜, 李幼平, 等. 2011年四川大學華西醫院老年患者門診疾病構成調查.中國循證醫學雜志, 2013, 13(5):536-542.
3.	徐珽, 吳斌, 李幼平, 等. 2011年四川大學華西醫院老年患者住院疾病構成調查.中國循證醫學雜志, 2013, 13(6):680-686.
4.	Available at: http://apps.who.int/classifications/icd10/browse/2010/en.
5.	Fukihara J, Watanabe N, Taniguchi H. Clinical Predictors of Response to EGFR Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer. Oncology, 2014, 86(2):86-93.
6.	楊曉軍, 李朝暉.采用DDD和DUI法分析我院門診抗感染藥物利用情況.現代應用藥學, 1997, 14(1):60-62.
7.	Scagliotti GV, Parikh P, Pawel J, et al. Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-na?ve patients with advanced-stage. J Clin Oncol, 2008; 26:3543-3551.
8.	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), Non-small cell lung cancer, Version 2. 2012.
9.	Yoshida T, Yamada K, Azuma K, et al. Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer:a retrospective analysis. Med Oncol, 2013; 30(1):349-356.
10.	蔡蕓, 閆麗莎, 魏宇寧, 等.王睿我院復方鎮痛藥氨酚羥考酮的臨床應用分析.中國新藥雜志, 2009, 9:862-864.
11.	聶海, 彭超, 郝杰, 等.唑來膦酸預防絕經婦女骨質疏松性骨折的Meta分析.第二軍醫大學學報, 2011, 32(9):985-990.
12.	時紅萍, 侯仰韶, 張秋寧, 等.唑來膦酸聯合化療治療非小細胞肺癌骨轉移的Meta分析.實用腫瘤雜志, 2014, 29(1):55-61.
13.	時紅萍, 張秋寧, 劉國慶, 等.唑來膦酸聯合放射治療治療惡性腫瘤骨轉移的Meta分析.中國循證醫學雜志, 2013, 13(7):858-867.
14.	石晶, 付凌雨, 劉云鵬, 等.唑來膦酸和帕米膦酸二鈉治療骨轉移癌疼痛療效比較的Meta分析.中華臨床醫師雜志(電子版), 2011, 5(17):5051-5056.
15.	王濤, 宋三泰, 江澤飛, 等.伊班膦酸治療惡性腫瘤性高鈣血癥的臨床研究.中華腫瘤雜志, 2004, 26(12):739-741.
16.	邢鐠元, 馮奉儀.伊班膦酸鈉治療惡性腫瘤骨轉移臨床評價.癌癥進展雜志, 2008, 6(1):11-15.
17.	陳鵬宇.唑來膦酸與帕米膦酸二鈉治療惡性腫瘤所致高鈣血癥的療效比較.南昌大學學報(醫學版), 2011, 51(9):33-36.
18.	王凱, 王栓科, 趙斌, 等.唑來膦酸與帕米膦酸二鈉治療惡性腫瘤骨轉移疼痛:療效與安全性對比的Meta分析.中國組織工程研究與臨床康復, 2010, 14(26):4791-4795.
19.	庫建偉, 苗松玉, 李汝敏.不同止吐方案預防化療所致嘔吐的對比研究.河南腫瘤學雜志, 2003, 16(2):145-146.
20.	董爽, 于世英.腫瘤化療所致惡心嘔吐現狀調查.中國循證醫學雜志, 2013, 13(6):687-691.
21.	陳世靈.胸腺肽制劑在腫瘤治療中的應用.中國醫藥導報, 2010, 15:9-10.

1. 伏紹宏, 李俊霞.四川省人口老齡化及老齡產業發展態勢及對策研究.理論與改革, 2012, 5(4):77-79.
2. 徐珽, 盧靜, 李幼平, 等. 2011年四川大學華西醫院老年患者門診疾病構成調查.中國循證醫學雜志, 2013, 13(5):536-542.
3. 徐珽, 吳斌, 李幼平, 等. 2011年四川大學華西醫院老年患者住院疾病構成調查.中國循證醫學雜志, 2013, 13(6):680-686.
4. Available at: http://apps.who.int/classifications/icd10/browse/2010/en.
5. Fukihara J, Watanabe N, Taniguchi H. Clinical Predictors of Response to EGFR Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer. Oncology, 2014, 86(2):86-93.
6. 楊曉軍, 李朝暉.采用DDD和DUI法分析我院門診抗感染藥物利用情況.現代應用藥學, 1997, 14(1):60-62.
7. Scagliotti GV, Parikh P, Pawel J, et al. Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-na?ve patients with advanced-stage. J Clin Oncol, 2008; 26:3543-3551.
8. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), Non-small cell lung cancer, Version 2. 2012.
9. Yoshida T, Yamada K, Azuma K, et al. Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer:a retrospective analysis. Med Oncol, 2013; 30(1):349-356.
10. 蔡蕓, 閆麗莎, 魏宇寧, 等.王睿我院復方鎮痛藥氨酚羥考酮的臨床應用分析.中國新藥雜志, 2009, 9:862-864.
11. 聶海, 彭超, 郝杰, 等.唑來膦酸預防絕經婦女骨質疏松性骨折的Meta分析.第二軍醫大學學報, 2011, 32(9):985-990.
12. 時紅萍, 侯仰韶, 張秋寧, 等.唑來膦酸聯合化療治療非小細胞肺癌骨轉移的Meta分析.實用腫瘤雜志, 2014, 29(1):55-61.
13. 時紅萍, 張秋寧, 劉國慶, 等.唑來膦酸聯合放射治療治療惡性腫瘤骨轉移的Meta分析.中國循證醫學雜志, 2013, 13(7):858-867.
14. 石晶, 付凌雨, 劉云鵬, 等.唑來膦酸和帕米膦酸二鈉治療骨轉移癌疼痛療效比較的Meta分析.中華臨床醫師雜志(電子版), 2011, 5(17):5051-5056.
15. 王濤, 宋三泰, 江澤飛, 等.伊班膦酸治療惡性腫瘤性高鈣血癥的臨床研究.中華腫瘤雜志, 2004, 26(12):739-741.
16. 邢鐠元, 馮奉儀.伊班膦酸鈉治療惡性腫瘤骨轉移臨床評價.癌癥進展雜志, 2008, 6(1):11-15.
17. 陳鵬宇.唑來膦酸與帕米膦酸二鈉治療惡性腫瘤所致高鈣血癥的療效比較.南昌大學學報(醫學版), 2011, 51(9):33-36.
18. 王凱, 王栓科, 趙斌, 等.唑來膦酸與帕米膦酸二鈉治療惡性腫瘤骨轉移疼痛:療效與安全性對比的Meta分析.中國組織工程研究與臨床康復, 2010, 14(26):4791-4795.
19. 庫建偉, 苗松玉, 李汝敏.不同止吐方案預防化療所致嘔吐的對比研究.河南腫瘤學雜志, 2003, 16(2):145-146.
20. 董爽, 于世英.腫瘤化療所致惡心嘔吐現狀調查.中國循證醫學雜志, 2013, 13(6):687-691.
21. 陳世靈.胸腺肽制劑在腫瘤治療中的應用.中國醫藥導報, 2010, 15:9-10.

Next Article
Drug Use Analysis on Over-60-year Inpatients with Lung Cancer in the West China Hospital of Sichuan University in 2011

Chinese Journal of Evidence-Based Medicine

Drug Use Analysis on Over-60-year Outpatients with Lung Cancer in the West China Hospital of Sichuan University in 2011

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content